IM
IMR.AU Imricor Medical Systems Inc
- Market cap
- AUD 4.61B
- P/E
- -
- P/B
- 17.45x
- ROE
- -345.9%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is IMR.AU undervalued?
Graham numberThe Graham number of Imricor Medical Systems Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Imricor Medical Systems Inc fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-345.9%), below 10%.
ROA 0/1
Return on assets (-136.6%) is below the industry median (-35.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (36.0%) is above the industry median (24.9%).
Revenue Growth 0/2
Revenue shrank 28.2% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (117.0%), above 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (17.4x) is above the industry median (4.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Imricor Medical Systems Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Imricor Medical Systems Inc
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company's products include Vision-MR Ablation Catheter 2.0, a MR-compatible cardiac ablation catheter; Vision-MR Diagnostic Catheter, a MR-compatible diagnostic catheter; NorthStar mapping system, a real-time, high-resolution s…
Full company profileImricor Medical Systems Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Imricor Medical Systems Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 704K | 566K | 1.34M | 640K | 702K | 696K | 816K | 616K | 959K | 303K | 98.6K |
| Gross Profit | 489K | 566K | 1.34M | 262K | -398K | -1.90M | -1.53M | -1.12M | -924K | -2.10M | -5.48M |
| Operating Income | -5.45M | -6.54M | -6.45M | -12.0M | -11.6M | -20.3M | -17.2M | -16.9M | -16.3M | -23.6M | -62.9M |
| EBITDA | -5.30M | -6.41M | -6.12M | -11.7M | -11.1M | -19.6M | -16.5M | -21.7M | -15.4M | -22.6M | -61.2M |
| Net Income | -5.49M | -6.71M | -7.30M | -14.8M | -13.1M | -20.6M | -17.5M | -22.6M | -29.7M | -26.2M | -101M |
| EPS | -0.06 | -0.07 | -0.08 | -0.15 | -0.11 | -0.15 | -0.12 | -0.14 | -0.13 | -0.08 | -0.30 |
| Balance Sheet | |||||||||||
| Total Assets | 3.47M | 3.00M | 16.1M | 10.5M | 33.6M | 26.9M | 13.7M | 8.31M | 21.6M | 45.8M | 73.6M |
| Total Liabilities | 7.50M | 8.25M | 2.59M | 3.49M | 4.75M | 4.46M | 6.19M | 17.1M | 29.0M | 34.3M | 44.5M |
| Shareholders' Equity | -4.03M | -5.25M | 13.5M | 7.03M | 28.8M | 22.4M | 7.51M | -12.8M | -7.38M | 11.5M | 29.1M |
| Cash & Short-term Investments | 2.89M | 2.26M | 12.4M | 5.05M | 25.1M | 18.5M | 5.69M | 832K | 15.7M | 40.8M | 67.5M |
| Total Debt | 2.28M | 2.99M | 9.93M | 1.27M | 1.39M | 1.74M | 4.45M | 10.4M | 21.3M | 26.0M | 34.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.05M | -5.65M | -6.34M | -6.63M | -12.2M | -17.5M | -16.5M | -13.0M | -15.6M | -19.7M | -56.1M |
| Capital Expenditure | 62.5K | 30.5K | 197K | 365K | 742K | 626K | 239K | 82.8K | 78.0K | 449K | 2.41M |
| Free Cash Flow | -4.11M | -5.68M | -6.54M | -6.99M | -13.0M | -18.1M | -17.1M | -13.1M | -15.7M | -20.2M | -58.5M |
| Ratios | |||||||||||
| ROE | - | - | -54.2% | -210.4% | -45.4% | -91.8% | -233.5% | - | - | -227.2% | -345.9% |
| ROA | -158.6% | -223.8% | -45.4% | -140.6% | -39.0% | -76.5% | -128.0% | -272.3% | -137.3% | -57.2% | -136.6% |
| Net Profit Margin | -780.6% | -1,186.5% | -543.5% | -2,313.3% | -1,862.4% | -2,952.3% | -2,148.8% | -3,675.6% | -3,094.9% | -8,661.6% | -102,011.8% |
| Debt to Equity | - | - | 0.74x | 0.18x | 0.05x | 0.08x | 0.59x | - | - | 2.25x | 1.17x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Imricor Medical Systems Inc dividends
Imricor Medical Systems Inc has not paid dividends in the last 9 fiscal years.
Who owns Imricor Medical Systems Inc
- Insiders 13.38%
- Institutions 16.54%
- Public & others 70.08%
- Shares outstanding 3.41B
- Free float 308M
Imricor Medical Systems Inc company profile
- Company name
- Imricor Medical Systems Inc
- Ticker
- IMR.AU
- ISIN
- AU0000054942
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 400 Gateway Boulevard, Burnsville, MN, United States, 55337
- Phone
- 952 818 8400
- Website
- imricor.com
About Imricor Medical Systems Inc
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company's products include Vision-MR Ablation Catheter 2.0, a MR-compatible cardiac ablation catheter; Vision-MR Diagnostic Catheter, a MR-compatible diagnostic catheter; NorthStar mapping system, a real-time, high-resolution soft tissue imaging of MRI to guide and visualize procedures with exceptional clarity; and Advantage-MR EP Recorder / Stimulator. The company through its Imricor Cardiovascular vertical provides integrated single session workflows for hospitals for MR imaging. It also offers Vision-MR Dispersive Electrode to minimize eddy currents induced on the device's conductive pads during MR scanning. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.
Imricor Medical Systems Inc management
6- Mr. Steven WedanPresident, CEO & Executive Chairman · born 1969
- Mr. Jonathon GutCFO & VP of Finance · born 1986
- Mr. Vic FabanoVice President of Operations · born 1962
- Mr. Greg EnglehardtVice President of Global Sales
- Mr. Nick TwohyVice President of Marketing & Business Development
- Mr. Zheng LiCompany Secretary